Articles with public access mandates - Shaji Kunnathu KumarLearn more
Not available anywhere: 31
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an …
SK Kumar, JG Berdeja, R Niesvizky, S Lonial, JP Laubach, M Hamadani, ...
The Lancet Oncology 15 (13), 1503-1512, 2014
Mandates: US National Institutes of Health
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind …
SK Kumar, SJ Harrison, M Cavo, J de la Rubia, R Popat, C Gasparetto, ...
The Lancet Oncology 21 (12), 1630-1642, 2020
Mandates: US National Institutes of Health, National Institute for Health Research, UK
The multiple myelomas—current concepts in cytogenetic classification and therapy
SK Kumar, SV Rajkumar
Nature reviews Clinical oncology 15 (7), 409-421, 2018
Mandates: US National Institutes of Health
A modern primer on light chain amyloidosis in 592 patients with mass spectrometry–verified typing
E Muchtar, MA Gertz, RA Kyle, MQ Lacy, D Dingli, N Leung, FK Buadi, ...
Mayo Clinic Proceedings 94 (3), 472-483, 2019
Mandates: US National Institutes of Health
Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the Mayo Clinic experience
TV Kourelis, RA Kyle, D Dingli, FK Buadi, SK Kumar, MA Gertz, MQ Lacy, ...
Mayo Clinic proceedings 92 (6), 908-917, 2017
Mandates: US National Institutes of Health
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
LJ Costa, BA Derman, S Bal, S Sidana, S Chhabra, R Silbermann, JC Ye, ...
Leukemia 35 (1), 18-30, 2021
Mandates: US National Institutes of Health
Clinical course and prognosis of non‐secretory multiple myeloma
SS Chawla, SK Kumar, A Dispenzieri, AJ Greenberg, DR Larson, RA Kyle, ...
European journal of haematology 95 (1), 57-64, 2015
Mandates: US National Institutes of Health
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria
E Muchtar, A Dispenzieri, N Leung, MQ Lacy, FK Buadi, D Dingli, ...
Leukemia 32 (10), 2240-2249, 2018
Mandates: US National Institutes of Health
High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis
A Dispenzieri, MA Gertz, SK Kumar, MQ Lacy, RA Kyle, AK Saenger, ...
Heart 100 (5), 383-388, 2014
Mandates: US National Institutes of Health
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
ML Khan, CB Reeder, SK Kumar, MQ Lacy, DE Reece, A Dispenzieri, ...
British journal of haematology 156 (3), 326-333, 2012
Mandates: US National Institutes of Health
Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity
LJ Costa, PN Hari, SK Kumar
Leukemia & lymphoma 57 (12), 2827-2832, 2016
Mandates: US National Institutes of Health
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains
S Sidana, N Tandon, A Dispenzieri, MA Gertz, FK Buadi, MQ Lacy, ...
Leukemia 32 (3), 729-735, 2018
Mandates: US National Institutes of Health
Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance
A Lakshman, S Paul, SV Rajkumar, RP Ketterling, PT Greipp, ...
Leukemia 32 (8), 1811-1815, 2018
Mandates: US National Institutes of Health
Clinical features and treatment outcomes of patients with necrobiotic xanthogranuloma associated with monoclonal gammopathies
LS Higgins, RS Go, D Dingli, SK Kumar, SV Rajkumar, A Dispenzieri, ...
Clinical Lymphoma Myeloma and Leukemia 16 (8), 447-452, 2016
Mandates: US National Institutes of Health
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis
E Muchtar, MA Gertz, TV Kourelis, S Sidana, RS Go, MQ Lacy, FK Buadi, ...
Leukemia 34 (4), 1135-1143, 2020
Mandates: US National Institutes of Health
Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis
D Dingli, TS Tan, SK Kumar, FK Buadi, A Dispenzieri, SR Hayman, ...
Neurology 74 (11), 913-918, 2010
Mandates: US National Institutes of Health
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse
S Sidana, N Tandon, A Dispenzieri, MA Gertz, FK Buadi, MQ Lacy, ...
Leukemia 33 (3), 730-738, 2019
Mandates: US National Institutes of Health
Implications of detecting serum monoclonal protein by MASS‐fix following stem cell transplantation in multiple myeloma
JP Abeykoon, DL Murray, I Murray, D Jevremovic, GE Otteson, ...
British journal of haematology 193 (2), 380-385, 2021
Mandates: US National Institutes of Health
A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis
C Heybeli, A Bentall, J Wen, MP Alexander, FK Buadi, FG Cosio, ...
Kidney international 99 (3), 707-715, 2021
Mandates: US National Institutes of Health
Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma
JP Abeykoon, J Vaxman, SV Patel, S Kumar, GC Malave, KS Young, ...
British journal of haematology 199 (1), 95-99, 2022
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program